ABIOMED, Inc. (NASDAQ:ABMD) price target increased to $146.00, reported today by Zacks Investment Research
- Updated: October 5, 2016
Displaying a price of $126.94, ABIOMED, Inc. (NASDAQ:ABMD) traded -0.13% lower on the day. With the last close up 16.84% from the two hundred day average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $122.19 and a 200-day moving average of $108.88. 311,635 shares of the stock were exchanged, down from an avg. volume of 446,075
ABIOMED, Inc. (NASDAQ:ABMD) had its stock price target increased to $146.00 by Zacks Investment Research in a report issued 10/05/2016. The new target price indicates a potential upside of 0.15% from the company's previous stock price.
Previously on 09/16/2016, Zacks Investment Research released a statement for ABIOMED, Inc. (NASDAQ:ABMD) raised the target price from $0.00 to $138.00. At the time, this indicated a possible upside of 0.11%.
Recent Performance Chart
With a total market value of $0, ABIOMED, Inc. has PE ratio of 135.33 with a one year low of $67.81 and a one year high of $131.16 .
Also covering ABIOMED, Inc.'s target, a total of 8 brokerages have issued a ratings update on ABIOMED, Inc.. The 12-month price target is $119.25 with 5 brokers rating the stock a strong buy, 2 firms rating the stock a buy, 2 analysts rating the company a hold, zero equity analysts rating the company a underperform, and lastly zero brokerages rating the company a sell.
General Information About ABIOMED, Inc. (NASDAQ:ABMD)
ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.